Abstract
Christofer S. Tautermann, Daniel Seeliger
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
Latest development in drug discovery on G protein-coupled receptors
10.2174/138920306778559403 · 2006
10.1016/j.ceb.2013.11.006
10.1016/j.ceb.2013.11.006
10.1038/nrd2199
10.1038/nrd2199
10.1016/s1359-6446(01)02131-6
10.1016/s1359-6446(01)02131-6
10.1177/1087057113498418
10.1177/1087057113498418
10.1124/mol.63.6.1256
10.1124/mol.63.6.1256
10.1080/07853890310024668
10.1080/07853890310024668
Novel assay technologies for the discovery of G protein-coupled receptor drugs
10.1007/978-1-61779-179-6_12 · 2011
Deorphanizing G protein-coupled receptors by a calcium mobilization assay
10.1007/978-1-61779-310-3_25 · 2011
Chemical probe identification platform for orphan GPCRs using focused compound screening: GPR39 as a case example
10.1021/ml400275z · 2013
An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs
10.1007/978-1-60327-317-6_4 · 2009
10.1038/nrd3859
10.1038/nrd3859
10.1016/j.bmcl.2014.07.009
10.1016/j.bmcl.2014.07.009
The use of GPCR structures in drug design
10.1016/b978-0-12-385952-5.00011-7 · 2011
10.4155/fmc.11.24
10.4155/fmc.11.24
10.1517/17460441.2013.783815
10.1517/17460441.2013.783815
Structure-based drug design applied to GPCRs: the holy grail realized
10.1042/bio03602023 · 2014
Recent developments in fragment-based drug discovery
10.1021/jm8000373 · 2008
10.1021/ci400731w
10.1021/ci400731w
10.1016/j.tips.2012.02.006
10.1016/j.tips.2012.02.006
10.1002/cmdc.201300382
10.1002/cmdc.201300382
10.1517/17460441.2013.794135
10.1517/17460441.2013.794135
10.1021/jm400140q
10.1021/jm400140q
Fragment screening of stabilized G-protein-coupled receptors using biophysical methods
10.1016/b978-0-12-381274-2.00005-4 · 2011
Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity
10.1021/cb300436c · 2012
Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design
10.1021/jm201376w · 2012
10.1016/j.drudis.2006.04.008
10.1016/j.drudis.2006.04.008
10.1016/j.bbamem.2013.07.013
10.1016/j.bbamem.2013.07.013
10.1016/j.sbi.2013.01.008
10.1016/j.sbi.2013.01.008
10.1021/bi401119m
10.1021/bi401119m
10.1371/journal.pone.0056742
10.1371/journal.pone.0056742
10.1016/j.jmb.2013.04.011
10.1016/j.jmb.2013.04.011
10.1038/nature10361
10.1038/nature10361
10.1038/nature09648
10.1038/nature09648
10.1126/science.1150577
10.1126/science.1150577
10.1038/nchem.1821
10.1038/nchem.1821
10.1073/pnas.1110499108
10.1073/pnas.1110499108
10.1002/minf.201100138
10.1002/minf.201100138
10.1146/annurev-biophys-042910-155245
10.1146/annurev-biophys-042910-155245
Molecular dynamics in drug design
2014
10.1063/1.3565032
10.1063/1.3565032 · doi-reference
10.1016/j.ymeth.2010.06.002
10.1016/j.ymeth.2010.06.002 · doi-reference
10.1016/j.tibs.2014.03.002
10.1016/j.tibs.2014.03.002 · doi-reference
10.1021/ja207494u
10.1021/ja207494u · doi-reference
10.1038/nature10867
10.1038/nature10867 · doi-reference
10.1124/pr.111.004580
10.1124/pr.111.004580 · doi-reference
10.1002/prot.20768
10.1002/prot.20768 · doi-reference
10.1074/jbc.m703255200
10.1074/jbc.m703255200 · doi-reference
10.1016/s0006-3495(04)74256-3
10.1016/s0006-3495(04)74256-3 · doi-reference
10.1159/000320814
10.1159/000320814 · doi-reference
10.1146/annurev.pharmtox.48.121806.154841
10.1146/annurev.pharmtox.48.121806.154841 · doi-reference
10.1002/(sici)1096-987x(199906)20:83.0.co;2-b
10.1002/(sici)1096-987x(199906)20:8<786::aid-jcc5>3.0.co;2-b · doi-reference
10.1002/(sici)1096-987x(199709)18:123.0.co;2-h
10.1002/(sici)1096-987x(199709)18:12<1463::aid-jcc4>3.0.co;2-h · doi-reference
10.1002/jcc.540130805
10.1002/jcc.540130805 · doi-reference
10.1063/1.470117
10.1063/1.470117 · doi-reference
10.1063/1.328693
10.1063/1.328693 · doi-reference
10.1063/1.2408420
10.1063/1.2408420 · doi-reference
10.1063/1.448118
10.1063/1.448118 · doi-reference
10.1002/jcc.21507
10.1002/jcc.21507 · doi-reference
ACPYPE — AnteChamber PYthon Parser interfacE
10.1186/1756-0500-5-367 · doi-reference
10.1002/jcc.20035
10.1002/jcc.20035 · doi-reference
10.1021/jp8001614
10.1021/jp8001614 · doi-reference
10.1021/j100308a038
10.1021/j100308a038 · doi-reference
10.1002/prot.22711
10.1002/prot.22711 · doi-reference
10.1021/jp901540t
10.1021/jp901540t · doi-reference
10.1016/s0006-3495(97)78845-3
10.1016/s0006-3495(97)78845-3 · doi-reference
10.1021/jm401219y
10.1021/jm401219y · doi-reference
10.1021/ct700301q
10.1021/ct700301q · doi-reference
10.1006/jmbi.1993.1626
10.1006/jmbi.1993.1626 · doi-reference
10.1146/annurev.biophys.29.1.291
10.1146/annurev.biophys.29.1.291 · doi-reference
Accuracy assessment and automation of free energy calculations for drug design
10.1021/ci4004199 · doi-reference
10.1371/journal.pcbi.1000435
10.1371/journal.pcbi.1000435 · doi-reference
10.1016/j.bpc.2013.10.007
10.1016/j.bpc.2013.10.007 · doi-reference
10.1021/jm800562d
10.1021/jm800562d · doi-reference
High-throughput molecular dynamics: the powerful new tool for drug discovery
10.1016/j.drudis.2012.03.017 · doi-reference
Molecular dynamics simulations and drug discovery
10.1186/1741-7007-9-71 · doi-reference